Teva’s Reslizumab Shows Reduction In Asthma Exacerbations In Clinical Studies – RTT News

Teva's Reslizumab Shows Reduction In Asthma Exacerbations In Clinical Studies
RTT News
Teva Pharmaceutical Industries Ltd. (TEVA: Quote) announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma …

and more »

View full post on asthma – Google News

Teva’s Reslizumab Delivers Clinically and Statistically Significant Reduction … – Wall Street Journal

Teva's Reslizumab Delivers Clinically and Statistically Significant Reduction
Wall Street Journal
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma …

View full post on asthma – Google News